© Olivier Cabaud A procedure that may help personalise anticancer therapies has just been developed by the CNRS, INSERM, and Aix-Marseille University scientists at the Centre d'Immunologie de Marseille-Luminy, in association with colleagues from the University of California San Francisco and the Marseille Public University Hospital System (AP-HM), with support from Canceropôle Provence-Alpes-Côte d'Azur. Their patented technique 1 reveals the energy status of cells, an indicator of their activity. It is presented in Cell Metabolism (1 December 2020). SCENITH: Single Cell ENergetIc metabolism by profilIng Translation inhibition. Patent: PCT/EP2020/060486 - Immunotherapies are a promising anticancer arsenal and work by mobilizing the immune system to recognize and destroy cancer cells. Currently, however, only a third of patients respond to immunotherapies: the tumour environment can be hostile to immune cells, depriving them of their source of energy, which diminishes treatment efficacy. The energy status of the various types of immune cells is a marker of their activity, and particularly of their proor antitumour action.
TO READ THIS ARTICLE, CREATE YOUR ACCOUNT
And extend your reading, free of charge and with no commitment.
Your Benefits
- Access to all content
- Receive newsmails for news and jobs
- Post ads
